Comparative Study of Allopurinol and Febuxostat Effects in Hyperuricemia and Chronic Kidney Disease Patients Using Serum Asymmetric Dimethyl Arginine as an Endothelial Dysfunction Marker.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202607678798356

Enrollment

150

Registered

2026-07-30

Start date

2024-05-20

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Disease

Interventions

Allopurinol

Febuxostat

Usual care

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? Adults (>=18 years old). ? Patients with CKD. ? Asymptomatic hyperuricemia. (SUA > 6 mg/dl) ? Stable doses for all medications, including antihypertensive medications, for at least three months preceding enrollment in this study. ? Stable renal function within at least 3 months before the enrollment in this study.

Exclusion criteria

Exclusion criteria: ? Pediatrics (<18 years old) ? Active infections. ? Acute kidney injury. ? Advanced malignancy. ? Serious disease. ? Patients on medications such as azathioprine, mercaptopurine, cyclosporine, pyrazinamide, or ethambutol. ? History of hypersensitivity to allopurinol or febuxostat.

Design outcomes

Primary

Measure	Time frame
Serum uric acid (mg/dL);Estimated GFR (mL/min/1.73 m2);Serum asymmetric dimethylarginine (µmol /L)	—

Secondary

Measure	Time frame
Urine albumin creatinine ratio (mg/gCr);Serum high sensitivity C-reactive protein (mg/L);LDL-cholesterol (mg/dL) ;Ankle brachial index	—

Countries

Egypt

Contacts

Public ContactMohamed Eldougdoug

Zagazig University Faculty of Pharmacy

mohwagdy@pharmacy.zu.edu.eg+201020908566

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026